Content area
Full text
BOULDER-Pharmion, a global biopharmaceutical company based in Boulder, has acquired Cabrellis Pharmaceuticals, expanding its oncology portfolio into solid tumor therapies in the United States and Europe.
Cabrellis has gained rights to Amrubicin, a third-generation synthetic anthracycline that is in Phase 2 trials...





